• 대한약침학회지
• /
• 제17권2호
• /
• pp.73-79
• /
• 2014

Objectives: This study was performed to analyze a 13-week repeated dose toxicity test of Sweet Bee Venom (SBV) extracted from bee venom and administered in Sprague-Dawley (SD) rats. Methods: Male and female 5-week-old SD rats were treated once daily with SBV (high-dosage group: 0.28 mg/kg; medium-dosage group: 0.14 mg/kg; or low-dosage group: 0.07 mg/kg) for 13 weeks. Normal saline was administered to the control group in a similar manner (0.2 mL/kg). We conducted clinical observations, body weight measurements, ophthalmic examinations, urinalyses, hematology and biochemistry tests, and histological observations using hematoxylin and eosin (H&E) staining to identify any abnormalities caused by the SBV treatment. Results: During this study, no mortality was observed in any of the experimental groups. Hyperemia and a movement disorder were observed around the area of in all groups that received SBV treatment, with a higher occurrence in rats treated with a higher dosage. Male rats receiving in the high-dosage group showed a significant decrease in weight during the treatment period. Compared to the control group, no significant changes in the ophthalmic parameters, the urine analyses, the complete blood cell count (CBC), and the biochemistry in the groups treated with SBV. Compared to the control group, some changes in organ weights were observed in the medium-and the high-dosage groups, but the low-dosage group showed no significant changes. Histological examination of thigh muscle indicated cell infiltration, inflammation, degeneration, and necrosis of muscle fiber, as well as fibrosis, in both the medium- and the high-dosage groups. Fatty liver change was observed in the periportal area of rats receiving medium and high dosages of SBV. No other organ abnormalities were observed. Conclusion: Our findings suggest that the No Observed Adverse Effect Level (NOAEL) of SBV is approximately 0.07 mg/kg in male and female SD rats.

• 대한전기학회:학술대회논문집
• /
• 대한전기학회 2003년도 학술회의 논문집 정보 및 제어부문 B
• /
• pp.540-543
• /
• 2003

This paper presents design and manufacture of RF type non-contact radiological dosage measuring device. It also concerns on the broad out-line and the ways of improvement about RF type non-contact radiation measuring device. Measuring radiological dosage with non-contact RF, the stability and efficiency of the measure have been improved by reforming constant current circuit. Furthermore, applying communication protocol in process makes it possible to achieve faster and more accurate communication than old circuit. On the base of those, RF type non-contact radiological dosage measuring device which consists of radiological dosage measuring module and Reader module has been designed and manufactured. While testing communication against embodied device, the possibility of the field application could be confirmed.

• 한국건축시공학회지
• /
• 제8권1호
• /
• pp.91-96
• /
• 2008

This study is to investigate the influence of the over-added chemical agents, such as water reducing agent(WRA) and AE water reducing agent(AEWRA), on the physical properties of concrete to estimate the degree of damage due to over-added chemical agents. For the fresh concrete, slump and slump flow increased with the increase of WRA and AEWRA as expected. Material segregation phenomenon was observed with the over dosage of lignin based AEWRA about 4 times larger than recommended dosage. The over dosage of AE water reducing agent about 4 times larger than recommended dosage resulted in an increase of air contents remarkably. The set retardation occurred greatly with the increase of AEWRA and WRA. For the properties of the hardened concrete corresponding to the over dosage of AEWRA, it is found that compressive strength of over added AEWRA and WRA concrete are much smaller than those of base and recommended dosage concrete proportionally due to associated increasing air content.

• 대한본초학회지
• /
• 제24권3호
• /
• pp.1-12
• /
• 2009

Objectives : The objective of this study was to compare, the potency of toxicity of Cantharidin containing dried Mylabis phalerata (MP) extract and it's modifier. Methods ： They were monitored at dosage level 2,000, 1,000, 500, 250 and 125 mg/kg, respectively. Changes of body weight, clinical signs, mortality, LD50, macroscopic changes of gastrointestinal tract and liver were observed after single oral dose of test articles with changes of serum Gastrin and Somatostatin levels. Results ： Dosage-dependent decrease of body weight and/or gains were demonstrated in dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, the body weights were significantly increased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently detected clinical signs in dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these clinical signs dramatically were decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependent increase of mortality rates were observed in dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, the mortalities were significantly decreased compared to that of equal dosage group of dried MP extract-dosing group. The LD50 of dried MP extract in male mice was dramaticlly increased in their modify, 265.86 vs 426.99 mg/kg. Dosage-dependently increase of number of hemorrhagic and/or erythematous spots detected in the gastrointestinal tracts of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal spots were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently increase of degrees of enlargement and congestion detected in the liver of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal signs were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently increase of serum gastrin levels of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal increase were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Dosage-dependently increase of serum somatostatin levels of dried MP extract-dosing groups, were also detected in modified and dried MP extract-dosing groups at 2,000 and 1,000 mg/kg-dosing group. However, below 500 mg/kg-dosing group, these abnormal increase were dramatically decreased compared to that of equal dosage group of dried MP extract-dosing group. Conclusions ： The toxicity of dried MP extract was reduced by their modify.

• Journal of Pharmaceutical Investigation
• /
• 제41권2호
• /
• pp.103-109
• /
• 2011

The objective of the study was to prepare self-microeulsifying drug delivery system (SMEDDS) incorporating atorvastatin calcium and evaluate its properties and oral bioavailability. Solubility of atorvastatin in various vehicles was determined. Pseudo-ternary phase diagrams were constructed to identify the good self-emulsification region. The droplet size distributions of the resultant emulsions were determined by dynamic light scattering measurement. The mean droplet size of chosen formulation (20% ethyl oleate, 40% tween-80, 40% Carbitol$^{(R)}$) was $23.4{\pm}1.3$ nm. The SMEDDS incorporating atorvastatin calcium appeared to be associated with better performance in dissolution and pharmacokinetic studies, compared with raw atorvastatin calcium. In dissolution test, the release percentage of atorvastatin from SMEDDS mixture could rapidly reach more than 95% within 3 min. Oral $AUC_{0{\rightarrow}8hr}$ values in SD rats was $1994{\pm}335\;ng{\cdot}hr/mL$, which significantly increased (P<0.05) compared with raw atorvastatin calcium. The SMEDDS formulation was relatively stable when stored at $4^{\circ}C$ during 3 months. Our studies illustrated the potential use of SMEDDS for the delivery of hydrophobic compounds, such as atorvastatin, by the oral route.

• Journal of Pharmaceutical Investigation
• /
• 제41권3호
• /
• pp.191-196
• /
• 2011

In this study simple and sensitive high performance liquid chromatographic method using a commercially available column, was developed and validated for the determination of zolpidem tartrate in human plasma. The developed method with suitable validation was applied to a bioequivalence study of two different kinds of zolpidem tartrate. Two different formulations containing 10 mg of zolpidem tartate (CAS : 99294-93-6) were compared in 24 healthy male volunteers in order to compare the bioavailability and prove the bioequivalence. The study was performed in an open, single dose randomized, 2-sequence, cross-over design in 24 healthy male volunteers with a one-week washout period. Blood samples for pharmacokinetic profiling were drawn at selected times during 12 h. The mean $AUC_{0-12h}$, $C_{max}$, $T_{max}$ and $T_{1/2}$ were $676.6{\pm}223.4$ $ng{\cdot}h{\cdot}mL^{-1}$, $177.4{\pm}34.2$ $ng{\cdot}mL^{-1}$, and $0.8{\pm}0.4$ and $3.5{\pm}2.1$, respectively, for the test formulations, and $640.7{\pm}186.6$ $ng{\cdot}h{\cdot}mL^{-1}$, $193.0{\pm}64.5$ $ng{\cdot}mL^{-1}$, and $0.9{\pm}0.4$ and $2.7{\pm}0.9$, respectively, for the reference formulation. Both primary target parameters $AUC_{0-12h}$ and $C_{max}$ were log-transformed and tested parametrically by analysis of variance (ANOVA). 90% confidence intervals of $AUC_{0-12h}$ and $C_{max}$ were in the range of acceptable limits of bioequivalence (80-125%). Based on these results, the two formulations of zolpidem tartate are considered to be bioequivalent.

• 대한방사선기술학회지:방사선기술과학
• /
• 제26권3호
• /
• pp.7-11
• /
• 2003

방사선과에 도입된 새로운 디지털 의료 영상 시스템은 많은 변화를 요구하고 있다. 기존의 F/S 시스템에서 부족하거나, 예측하지 못하는 일부분을 대체로 만족하는 수준에 이르렀다. 하지만, 영상의 질과 환자의 피폭선량에서는 아직도 구체적인 자료가 제시되지 않고 있는 것이 현실이다. 이에 본 연구는 기존의 F/S 시스템의 의료 영상과 디지털 의료 영상을 비교하는데 있어서 환자의 피폭선량의 관점에서 실험을 하였으며, 실험결과 값을 이용하여 보다 우수한 환자 서비스 개선을 위한 DR 시스템의 영상의 질과 피폭선량의 측면에서 자료를 제시하고자 연구하였다.

• Journal of Korean Biological Nursing Science
• /
• 제14권3호
• /
• pp.174-182
• /
• 2012

Purpose: The objective of this study was to identify predictors of drug calculation competence of nursing students. Methods: A total of 120 students were recruited from 3 universities from November 10 to 20, 2011. The instruments for this study were drug calculation competence, self-efficacy for drug dosage calculation, anxiety for drug dosage calculation, and the academic self-efficacy scale. The data were analyzed by descriptive analysis, chi-square test, t-test, Scheffe test, partial correlation coefficients, and stepwise multiple regression using the SPSS 18.0 program. Results: The mean score of good competence group was $0.67{\pm}0.08$ and the mean score of no-good competence group was $0.42{\pm}0.10$. The drug calculation competence was positively related to self-efficacy for drug dosage calculation and academic self-efficacy scale, but negatively related to anxiety for drug dosage calculation after controlling personal attributes. The main predictors of drug calculation competence in nursing students were identified as anxiety for drug dosage calculation (${\beta}$=-.25, p=.046), academic self-efficacy (${\beta}$=.19, p=.035). These two factors explained about 10% of variance in drug calculation competence. Conclusion: Based on the results, the strategies reducing the anxiety for drug dosage calculation and improving the academic self-efficacy should be developed and implemented.

• 한국물환경학회지
• /
• 제27권2호
• /
• pp.188-193
• /
• 2011

The effects of coagulants on the microorganisms when they are injected directly into the biological treatment facility for T-P removal have been easily observed from the results of past experiments. As such this study is set out to derive the effective plans for the coagulant dosage by analyzing the effects of the injected coagulant on the microbial activity during the chemical treatment for T-P removal. The research methods entailed the assessment of removal efficiency of T-P according to the coagulant dosage while changing the molar ration between Alum and influent phosphorus. At the same time Specific Oxygen Uptake Rate (SOUR) according to the coagulant dosage was measured. SOUR was used as a method for indirect assessment of the microbial activity according to the coagulant dosage. The results from the study showed that with the increase in the alum dosage, the removal efficiency T-P tended to increase. On the other hand, the increase in coagulant dosage resulted in the decrease in SOUR, which indicates the decrease in the microbial activity. Such reduction in the activity could be explained by the increase in the concentration of removal efficiency of $TBOD_5$. Based on experiment results from the study, it is determined that coagulant dosage affects the microbial activity. Moreover, the indirect assessment on the microbial activity using SOUR is considered possible.

• Journal of Ginseng Research
• /
• 제24권2호
• /
• pp.99-105
• /
• 2000

본 논문은 인삼의 한의학적 응용과 현재 각국별 인삼의 복용기준 및 그 동안 수행된 임상실험을 중심으로 인삼의 응용과 복용량에 대한 문헌적 고찰을 하였다. 인삼분말 기준 복용량은 특별히 처방에 기술되어 있지 않은 한 1회 3~4 g정도 복용하는 것이 보편적 복용량으로 간주되며, 인삼제품도 이에 상당하는 인삼량으로 복용하면 될 것으로 사료된다. 다만 서구권의 경우는 인삼을 의약품으로 분류하여 복용량을 하루 1-2정도로 규정하고 있고 임상실험에서 사용된 인삼투여용량은 대부분 1g 이하로 되어 있다 서구에서의 인삼복용량 설정은 그 동안 인삼의 안전성(부작용과 역작용 등)과 관련된 사례보고 등에 근거하여 그 복용기준을 설정한 것으로 이해된다. 그러나 동서양간 인삼복용량의 차이점에 대해서는 동양인과 서구인들 간의 식생활 차이 또는 인종적 차이에 기인한 인삼의 복용 반응의 차이인지에 대해서 추후 검토되어야 할 사항이다. 아울러 인삼의 투여용량별 효과의 차별성이 있는지, 금후 인삼의 적정 투여용량 설정과 관련하여 인체실험을 통한 활성성분의 체내동태(Pharmacokinetics)와 자생체내 이용효율(Bioavailability)에 대한 연구가 이루어져야할 것이다.